IMUNON Reports Positive IDMC Opinion For IMNN-001 In Ovarian Cancer

IMUNON received a positive recommendation from an Independent Data Monitoring Committee for its Phase 2 minimal residual disease trial of IMNN-001, an IL-12-based treatment candidate for ovarian cancer. The favorable trial-monitoring outcome supports continued development of the clinical-stage oncology program and is a positive catalyst for IMNN shares, though efficacy data and regulatory outcomes remain pending.